Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the chemical formula C18H14N2O9S2 and a molecular weight of approximately 466.44 g/mol. It is not an approved drug and has no known clinical indications or marketed formulations. The molecule has been studied as an experimental inhibitor of protein tyrosine phosphatase 1B (PTP1B), a target implicated in metabolic disorders such as diabetes and obesity. Structural studies have shown it binds to PTP1B's active site[5]. There are no reported clinical trials or approvals for this compound as a pharmaceutical agent[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 7-(1,1-Dioxo-1h-Benzo[D]Isothiazol-3-Yloxymethyl)-2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid.